ArticleGynecologic oncology reports2025

Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer.

Susan M Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.